Education
About Us
Working with TipRanks
Follow Us
Annovis Bio (ANVS)
NYSE:ANVS
ANVS Stock Chart & Stats
$1.89
-$0.04(-0.79%)
At close: 4:00 PM EST
$1.89
-$0.04(-0.79%)
Day’s Range― - ―
52-Week Range$1.11 - $8.93
Previous CloseN/A
Volume368.97K
Average Volume (3M)1.04M
Market Cap
$49.36M
Enterprise Value$25.15M
Total Cash (Recent Filing)$17.13B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.07
Next Earnings
Nov 05, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding26,114,670
10 Day Avg. Volume492,676
30 Day Avg. Volume1,037,097
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)6.58
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.06
Forecast
1Y Price Target
$11.67Price Target Upside517.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker DataAnnovis announced novel biomarker data supporting the disease-modifying potential of Buntanetap in Alzheimer's disease.
Clinical Trial ProgressThe ongoing Phase 3 study of Buntanetap is designed to provide further evidence of disease-modifying effects with a longer treatment period.
Intellectual PropertyAnnovis announced the completion of patent transfer to the crystalline form of buntanetap, extending the IP estate around both forms of the drug to 2046.
Bears Say
Financial ForecastReducing the 12-month price target to $10 from $12 reflects a lengthier time to potential approval of buntanetap.
Risks And ChallengesRisks include failure to initiate trials in a timely manner, negative clinical data for buntanetap, inability to establish partnerships to commercialize buntanetap, failure to secure approval, slower-than-anticipated market uptake, and possible medium-term dilution risk.
Annovis Bio News
ANVS FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was $1.11 and its highest was $8.93 in the past 12 months.
What is Annovis Bio’s market cap?
Annovis Bio’s market cap is $49.36M.
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is Nov 05, 2025 which is yesterday.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Aug 12, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.402 by $0.082.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate is -0.31.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 26,114,670 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.402. Following the earnings report the stock price went down -2.527%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in ANVS
Annovis Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.67 (517.46% Upside)
$11.67 (517.46% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 11.5%
Last 30 Days ▲ 11.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.77%
12-Months-Change
Fundamentals
Return on Equity
-365.03%
Trailing 12-Months
Asset Growth
325.14%
Trailing 12-Months
Company Description
Annovis Bio
Annovis Bio (ANVS) is a clinical-stage pharmaceutical company focused on developing innovative therapies for neurodegenerative diseases. The company is primarily engaged in the research and development of drugs aimed at treating conditions such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative disorders. Annovis Bio is committed to creating solutions that can halt or reverse the progression of these debilitating diseases by targeting the underlying biological pathways involved in neurodegeneration.
ANVS Stock 12 Month Forecast
Average Price Target
$11.67
▲(517.46% Upside)
Technical Analysis
Generation Bio
―
PolyPid
―
BioAtla
―
Coeptis Therapeutics Holdings
―
MiNK Therapeutics
―
Ownership Overview
14.51% Insiders
4.33% Mutual Funds
0.11% Other Institutional Investors
77.70% Public Companies and
Individual Investors